



HAL
open science

Apathy predicts rate of cognitive decline over 24 months in premanifest Huntington's disease

S. Andrews, D. Langbehn, D. Craufurd, A. Durr, B. Leavitt, R. Roos, S.
Tabrizi, J. Stout

► To cite this version:

S. Andrews, D. Langbehn, D. Craufurd, A. Durr, B. Leavitt, et al.. Apathy predicts rate of cognitive decline over 24 months in premanifest Huntington's disease. *Psychological Medicine*, 2020, 51 (8), pp.1338-1344. 10.1017/S0033291720000094 . hal-04610608

HAL Id: hal-04610608

<https://hal.sorbonne-universite.fr/hal-04610608>

Submitted on 10 Jul 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Word Count: 3540

Tables: 3

Figures: 1

Apathy predicts rate of cognitive decline over 24 months in premanifest Huntington's disease

Andrews, S.C.^{1,2,3}, Langbehn, D.R.⁴, Craufurd, D.^{5,6}, Durr, A.⁷, Leavitt, B.R.⁸, Roos, R.A.⁹,
Tabrizi, S.J.¹⁰, Stout, J.C.¹, and the TRACK-HD Investigators*

¹School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia

²Neuroscience Research Australia, Sydney, NSW, Australia

³School of Psychology, University of New South Wales, Sydney, NSW, Australia

⁴Department of Psychiatry, University of Iowa, Iowa City, USA

⁵Manchester Centre for Genomic Medicine, Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

⁶St. Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK

⁷Sorbonne Université, Institut du Cerveau et de la Moelle épinière (ICM), AP-HP, Inserm U 1127, CNRS UMR 7225, University Hospital Pitié-Salpêtrière, Paris, France

⁸Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada

⁹Dept Neurology LUMC, Universiteit Leiden, Leiden, The Netherlands

¹⁰Department of Neurodegenerative Diseases, University College London, Queen Square Institute of Neurology, and National Hospital for Neurology and Neurosurgery, London, UK

Correspondence to: Prof. Julie C. Stout, Monash Institute of Cognitive and Clinical Neurosciences, 18 Innovation Walk, Clayton VIC 3800 Australia; julie.stout@monash.edu

*TRACK-HD Investigators:

Canada—A Coleman, R Dar Santos, J Decolongon, A Sturrock (University of British Columbia, Vancouver).

France—E Bardinet, C Jauffret, D Justo, S Lehericy, C Marelli, K Nigaud, R Valabrègue (APHP, Hôpital Salpêtrière, Paris).

Germany—N Bechtel, R Reilmann (University of Münster, Münster); A Hoffmann, P Kraus (University of Bochum, Bochum); B Landwehrmeyer (University of Ulm)

Netherlands—SJA van den Bogaard, E M Dumas, J van der Grond, EP t'Hart, C Jurgens, M-N Witjes-Ane (Leiden University Medical Centre, Leiden).

UK—N Arran, J Callaghan (St Mary's Hospital, Manchester); C Frost, R Jones (London School of Hygiene and Tropical Medicine, London); N Fox, N Hobbs, N Lahiri, R Ordidge, G Owen, T Pepple, J Read, M Say, R Scahill, E Wild (University College London, London); S Keenan (Imperial College London, London); D M Cash (IXICO, London); S Hicks, C Kennard (Oxford)

USA—E Axelson, H Johnson, D Langbehn, C Wang (University of Iowa, Iowa City, IA); S Lee, W Monaco, H Rosas (Massachusetts General Hospital, Harvard, MA); C Campbell, S Queller, K Whitlock (Indiana University, IN).

Australia—C Campbell, M Campbell, E Frajman, C Milchman, A O'Regan (Monash University, Victoria).

Financial Support

Track-HD was supported by the CHDI/High Q Foundation, a non-for-profit organisation dedicated to finding treatments for Huntington's disease. Dr. Andrews is supported by a fellowship from the Huntington's Disease Society of America.

Abstract

Background. Cognitive impairment is a core feature of Huntington's disease (HD), however, the onset and rate of cognitive decline is highly variable. Apathy is the most common neuropsychiatric symptom of HD, and is associated with cognitive impairment. The aim of this study was to investigate apathy as a predictor of subsequent cognitive decline over 2 years in premanifest and early HD, using a prospective, longitudinal design.

Methods. 118 premanifest HD gene carriers, 111 early HD and 118 healthy control participants from the multi-centre TRACK-HD study were included. Apathy symptoms were assessed at baseline using the apathy severity rating from the Short Problem Behaviours Assessment. A composite of 12 outcome measures from 9 cognitive tasks was used to assess cognitive function at baseline and after 24 months.

Results. In the premanifest group, after controlling for age, depression and motor signs, more apathy symptoms predicted faster cognitive decline over 2 years. In contrast, in the early HD group, more motor signs, but not apathy, predicted faster subsequent cognitive decline. In the control group, only older age predicted cognitive decline.

Conclusions. Our findings indicate that in premanifest HD, apathy is a harbinger for cognitive decline. In contrast, after motor onset, in early diagnosed HD, motor symptom severity more strongly predicts of rate of cognitive decline.

Introduction

Huntington's disease (HD) is an autosomal-dominant neurological disorder caused by a CAG expansion in the huntingtin gene (Walker, 2007). Onset of the disease can be at any age but usually occurs in mid-life, with larger CAG repeat numbers associated with younger onset, and the first signs typically involuntary movements, psychiatric symptoms and cognitive decline (Walker, 2007). Clinical definition HD diagnosis requires the presence of motor signs, however subtle cognitive and psychiatric symptoms often occur up to 15 years prior to diagnosis (Duff et al., 2010; Saul Martinez-Horta et al., 2016; Paulsen & Long, 2014; Stout et al., 2011). All people with HD experience progressive cognitive decline, although the onset and progression of cognitive impairment is highly variable (Papoutsis, Labuschagne, Tabrizi, & Stout, 2014). Cognitive decline contributes to functional disability, reducing patients' ability to drive, work, and live independently (Ross, Pantelyat, Kogan, & Brandt, 2014; Tabrizi et al., 2013). Therefore, the ability to identify those most at risk of early and rapid cognitive decline would be beneficial in triggering early interventions aimed at supporting patients and their families to cope with cognitive change. Apathy, a loss of motivation and reduction in voluntary, goal-directed behaviour, is a common early sign of HD which may be a harbinger of cognitive impairment. Apathy is very common in HD. For example, Martinez-Horta et al. found clinically significant apathy in 23% of premanifest HD participants, who were on average more than a decade prior to diagnosis, and 62% in the early manifest HD group (2016). This is in comparison to a prevalence of 36% in Parkinson's disease (Garcia-Ramos, Villanueva, del Val, & Matias-Guiu, 2010), and 49% in Alzheimer's disease (Nobis & Husain, 2018).

Apathy predicts longitudinal cognitive decline in other neurodegenerative diseases. For example in Parkinson's disease (Dujardin, Sockeel, Delliaux, Destee, & Defebvre, 2009) and Alzheimer's disease (Starkstein, Jorge, Mizrahi, & Robinson, 2006), participants who

were more apathetic at baseline were more likely to show cognitive decline over 1-4 years than participants who were non-aphathetic at baseline. Similarly, a longitudinal study of people with Mild Cognitive Impairment revealed that those with apathy were more likely to develop Alzheimer's disease than those without apathy (Richard et al., 2012; Robert et al., 2008). Why might this be? Levy and Dubois (2006) proposed three prefrontal-subcortical circuits important for initiation, cognition/planning, and emotional-affective/motivation aspects of apathy, and argued the disruption of any of these circuits could cause manifestations of apathy. Consistent with this proposal, two recent studies have found a relationship between apathy and structural brain changes within these circuits in early HD. In one study, the presence of apathy was associated with smaller thalamus volumes in premanifest and early HD participants from the TRACK-HD study (Baake et al., 2018). Additionally, an MRI-PET study found that in a sample of 40 patients with early stage HD, higher apathy severity was associated with lower grey matter volume in subcortical regions, temporal lobes, and anterior cingulate cortex, as well as lower brain glucose metabolism in the prefrontal cortex, temporal lobes, insula, and precuneus (S. Martinez-Horta et al., 2018). These areas make up a complex cortico-subcortical network critical for reward- and emotion-processing. Importantly, lower grey matter volume and reduced metabolism in these regions were also associated with poorer cognitive task performance. Given degeneration occurs in parts of this cortico-subcortical reward-processing network years before the detection of cognitive impairment (Papoutsis et al., 2014), apathy may be an early sign of disruption to the brain's reward- and emotion-processing circuitry, which, with disease progression, eventually manifests in cognitive impairment (Palminteri et al., 2012).

Evidence from at least three previous studies suggests that apathy and cognitive impairment are associated in HD. For example, two cross-sectional studies have found that people with diagnosed HD classified as apathetic are more likely to have cognitive

impairment, compared to those classified as non-apathetic (Baudic et al., 2006; Sousa et al., 2018). Additionally, Reedeker and colleagues assessed apathy and cognition over 2 years in a mixed premanifest and motor-manifest HD sample, and reported that slower processing speed at baseline predicted persistent apathy (2011). Apathy as a predictor of subsequent cognitive decline has not been examined in premanifest or manifest HD, however, in early HD, one study found that apathy predicted subsequent functional decline over 36 months (Tabrizi et al., 2013). Given the relationship between cognition and everyday function in HD, apathy may also predict subsequent cognitive decline in HD. In the current study, we examined severity of apathy symptoms as a predictor of cognitive decline over 2 years in premanifest and early HD, independent of age, motor or depression symptoms.

Method

Participants

Our data analyses included 118 premanifest gene carriers, 111 early HD and 118 healthy control participants from the TRACK-HD study who completed baseline and 24-month visits. Full details of the TRACK-HD study have been reported elsewhere (Stout et al., 2012; Tabrizi et al., 2009). Briefly, participants were enrolled at four sites, London (UK), Paris (France), Leiden (Netherlands), and Vancouver (Canada). At baseline participants were aged between 18-65 years and had no history of major neurological disease (other than HD), major psychiatric disorder or severe head injury. Premanifest participants had a baseline total motor score (TMS) of 5 or lower on the United Huntington's Disease Rating Scale (UHDRS; Huntington Study Group, 1996). Early HD participants had a baseline UHDRS total functional capacity (TFC) score of between 7 and 13, indicating minimal to moderate clinical impairment (Shoulson & Fahn, 1979). Control participants were age- and gender-matched to the combined premanifest and early HD groups at baseline. Participant characteristics are

presented in Table 1. The study was approved by local ethics committees and participants gave written informed consent.

Assessment of Apathy

Apathy symptom severity at baseline was measured using severity rating from the lack of initiative (apathy) item from the Short Problem Behaviours Assessment for Huntington's disease (PBA-s; Callaghan et al., 2015; Orth et al., 2010). The PBA-s is a semi-structured interview conducted by a clinician-rater with the participant and an informant, and was designed to obtain information about current behaviour. The short version has 11 items, each measuring a different behavioural problem, such as apathy, depression, or irritability. Each behaviour is rated for both severity and frequency on a 5-point scale, ranging from 0 (absent) to 4 (severe). The measure has good inter-rater reliability (Callaghan et al., 2015). Because of concerns regarding the validity of the frequency rating (McNally, Rickards, Horton, & Craufurd, 2015), we used the severity rating from the apathy item as the measure of baseline apathy. Baseline apathy scores, along with the proportion of participants rated in the clinical range (severity score ≥ 2) within each group are shown in Table 1.

Table 1 Baseline participant characteristics

	Healthy Controls	Pre-HD	Early HD
N	118	111	118
Age (years)	46.30 (10.34, 23–66)	41.21 (9.07, 19-64)	49.06 (9.85, 23-64)
Women	66 (56%)	60 (54%)	64 (54%)
Education			
Primary/Middle School	24 (20.30%)	16 (14.41%)	30 (25.42%)
High School	13 (11.02%)	25 (22.52%)	27 (22.88%)
Technical college	37 (31.36%)	26 (23.42%)	21 (17.80%)
University Degree	44 (37.29%)	44 (39.64%)	40 (33.90%)
CAG repeat length	-	43.07 (2.43, 39-52)	43.68 (2.92, 39-59)
Disease- burden score	-	294.20 (48.59, 172-413)	378.60 (70.63, 210-566)
Centres			
Leiden	30 (25.42%)	30 (27.03%)	29 (24.58%)
London	29 (24.58%)	29 (26.13%)	30 (25.42%)
Paris	26 (22.03%)	23 (20.72%)	26 (22.03%)
Vancouver	33 (27.97%)	29 (26.13%)	33 (27.97%)
UHDRS TMS	1.48 (1.70, 0-7)	2.52 (1.55, 0-8)	23.81 (10.85, 5-52)
UHDRS TFC	12.98 (.13, 12-13)	12.82 (.60, 9-13)	10.83 (2.02, 7-13)

BDI Total	6.64 (6.65, 0-31)	7.68 (8.41, 0-42)	10.84 (9.40, 0-40)
PBA Apathy Score	.25 (.67, 0-4)	.49 (.94, 0-4)	1.12 (1.18, 0-4)
Apathy present	8 (6.7%)	17 (15.3%)	46 (39%)

Data are mean (SD, range) or number (%). Disease-burden score is calculated as age x [CAG-35.5]. UHDRS TMS – UHDRS Total Motor Score: Possible scores range from 0 – 124; UHDRS TFC – UHDRS Total Functional Capacity: Possible scores range from 0-13; BDI Total – Beck Depression Inventory Total Score; PBA Apathy Score – Problem Behaviour Assessment Apathy Severity Score: Possible scores range from 0 – 4. Apathy Present: Proportion of participants above cut-off for clinical apathy ≥ 2 .

Cognitive Assessment

Cognitive function was assessed by deriving a composite based on 12 primary cognitive outcome variables from 9 cognitive tasks, as proposed by Stout et al. (2012) (see Table 2 for a description of each outcome measure). These cognitive tasks were originally selected as part of the TRACK-HD battery to be the most sensitive to cognitive change in pre-HD (Tabrizi et al., 2009) and included tests of psychomotor speed, attention, working memory, planning, set-shifting, emotion recognition and odour identification. Odour identification was included in the cognitive composite as there is a wealth of evidence that higher order olfactory tasks are strongly associated with executive functioning and semantic memory abilities in both healthy populations (Hedner, Larsson, Arnold, Zucco, & Hummel, 2010; Larsson, Finkel, & Pedersen, 2000; Schab, 1991), and HD (Delmaire et al., 2013; Nordin, Paulsen, & Murphy, 1995). Cognition was assessed annually throughout the TRACK-HD study, and for this study, we included participants' baseline and 24-month cognitive results. We defined change in cognition as change in performance from baseline (Visit 1) to 24 months (Visit 3).

Table 2 Tasks contributing to cognitive composite

Task	Primary variable	Cognitive Domain
Symbol Digit Modalities Test (SDMT)	Number correct	Psychomotor speed, working memory
Stroop Word Reading	Number correct	Psychomotor speed, word reading
Trails A	Completion time (s)	Attention, psychomotor speed
Trails B	Completion time (s)	Attention, set shifting, psychomotor speed
Paced Tapping (1.8 & 3 Hz)	Precision (1/SD of ITI in 1/ms)	Psychomotor, movement timing (slow and fast)

Serials 2 s with tapping	Number correct subtractions	Psychomotor speed, dexterity with cognitive load
Spot the Change set size 5	Number correct adjusted for guessing (k)	Visual working memory
Emotion Recognition	Number correct combined negative emotions	Perceptual facial affect recognition
University of Pennsylvania Smell Identification Test (UPSIT)	Number correct	Odour identification, executive functioning, semantic memory
Circle Tracing direct and indirect	Annulus length (log cm)	Motor speed, planning, and correction

Assessment of Depression

Severity of depression symptoms at baseline was measured using the total score of the Beck Depression Inventory II (BDI-II; Beck, Steer, & Brown, 1996), a commonly used 21 item self-report measure. Each item is scored from 0 to 3, with higher scores indicating higher severity of symptoms. The maximum total score is 63.

Statistical Analyses

In order to create the cognitive composite, for each participant, we first standardized the task scores of component cognitive measures by using the baseline data combined across the premanifest HD, early HD, and control groups as the population. The average of the 12 standardised scores at baseline and at 24 months was then calculated, and difference between these values created the change in cognitive composite, where a positive value represented an improvement over 24 months, whereas a negative value represented a decline over 24 months. Because 36% of early diagnosed HD subjects were missing data from one or more cognitive tests at one of the visits, we used multiple imputation (MI; Rubin, 1987) to simulate a range of plausible values for missing scores. Imputation was done separately for the premanifest group, the early HD group, and the control group. For the MI model, we used the 12 cognitive variables contributing to the composite, as well as BDI and PBA-Apathy, age, gender and education. Twenty sets of data were imputed per group. Final model estimates and hypothesis tests were derived by applying Rubin's procedures to the analyses of

each imputed data set (Carpenter & Kenward, 2013; Rubin, 1987). All statistical analyses were performed using SAS/STAT[®] software, version 14.1 (SAS Institute Inc, 2015).

Pearson correlations were used to assess the association between PBA-Apathy severity score and BDI-II depression score, UHDRS motor score and age for each group at baseline. We used statistical modelling to assess the impact of apathy and other measures at baseline on the subsequent longitudinal change in the cognitive composite score. We used least squares regression with the longitudinal cognitive score change as the outcome.

Depending on the model, the predictors were chosen from among the baseline values of age, UHDRS motor score (square root transformed), BDI-II depression score, and PBA-Apathy Severity.

Results

Cognitive change over 24 months by group

Figure 1 shows the mean change in cognitive composite score over 24 months for each group, where the control and premanifest groups show *positive* mean change scores, reflecting improved task performance due to practice effects (Stout et al., 2012), and the early HD group show a *negative* mean change score indicating more marked cognitive decline occurred the 24 month interval. The early HD group showed significantly more cognitive decline than the control group, based on the multiple imputation data ($t = -7.82, p = <.001$). The premanifest group showed an intermediate level of cognitive change, that was not significantly different to the control group ($t = -1.57, p = .12$).

INSERT FIGURE 1

Bivariate correlations between apathy and age, total motor score and depression

Pearson correlations revealed that at baseline, a higher apathy score was associated with a higher depression score for controls ($r = .53, p < .001$), premanifest participants ($r = .63, p < .001$), and early HD participants ($r = .45, p < .001$). A higher apathy score also related to a higher UHDRS Total Motor Score for early diagnosed HD participants ($r = .43, p < .001$), but not premanifest participants ($r = .07, p = .49$) or controls ($r = .05, p = .60$). There were no significant associations between apathy and age for any group (all $ps < .21$).

Assessing apathy as a predictor of cognitive change over 24 months

In the premanifest group, we initially entered only baseline age and apathy scores into the model, and found that older age predicted slower cognitive decline ($\beta = .29, p = .002$) but apathy was not a significant predictor ($\beta = -.09, p = .37$). We then added self-reported depression to the model, and found that then apathy emerged as a significant predictor, with more apathy at baseline predicting faster cognitive decline ($\beta = -.27, p = .028$). Baseline age and depression scores were also independent predictors in the model (age: $\beta = .31, p < .001$; depression: $\beta = .30, p = .01$), with older age and higher levels of self-reported depression predicting *slower* cognitive decline. Finally, motor score was not a significant predictor of cognitive decline when it was added to the model, however apathy, age and depression remained as significant predictors. The final model is shown in Table 3, and accounted for 16.1% of the variance in cognitive decline.

Table 3 Final Multiple Regression Model of Cognitive Composite Change for Each Group

	<i>Estimate</i>	<i>SE</i>	β	<i>t</i>	<i>p</i>
<i>Premanifest HD Group</i>					
Intercept	-.140	.097		-1.45	.152
Baseline Age	.007	.002	.313	3.53	<.001**
Baseline TMS	-.009	.029	-.031	-.32	.748
Baseline BDI Score	.007	.003	.300	2.61	.010*
Baseline Apathy Score	-.060	.027	-.271	-2.26	.027*
<i>Early HD Group</i>					

Intercept	.085	.16		.053	.60
Baseline Age	.006	.003	.23	2.48	.015*
Baseline TMS	-.097	.027	-.38	-3.5	<.001**
Baseline BDI Score	.004	.004	.14	1.3	.20
Baseline Apathy Score	-.037	.027	-.15	-1.36	.18
<i>Control Group</i>					
Intercept	.59	.096		6.18	<.001**
Baseline Age	-.007	.002	-.35	-3.75	<.001**
Baseline BDI Score	-.004	.004	-.13	-1.03	.31
Baseline Apathy Score	-.002	.037	-.005	-.04	.96

* $p < .05$, ** $p < .01$. TMS = UHDRS Total Motor Score (Square Root Transformed); BDI = Beck Depression Inventory; Apathy Score = Problem Behaviors Assessment Apathy Severity Score.

In the early HD group, with only baseline age and apathy scores entered into the model, more baseline apathy predicted faster cognitive decline ($\beta = -.24$, $p = .01$), whereas age was not a significant predictor ($\beta = .16$, $p = .14$). Once motor score was added to the model, however, apathy was no longer a significant predictor ($\beta = -.09$, $p = .40$). Instead, in contrast to the premanifest group, for the early HD group more severe motor signs *did predict* faster cognitive decline ($\beta = -.37$, $p = .001$), and younger age also predicted faster cognitive decline ($\beta = .22$, $p = .02$). Self-reported depression was not a significant predictor when added to the model, and the overall variability accounted for by the model was largely unchanged. The final model, in Table 3, accounts for 19.6% of the variance in cognitive decline.

Finally, in the control group, with baseline age and apathy scores entered into the model as predictors of cognitive decline over 2 years, age emerged as a significant predictor of cognitive decline, but in contrast to the HD groups (for whom older age predicted *slower* cognitive decline), older age at baseline predicted *faster* cognitive decline ($\beta = -.35$, $p < .001$). Apathy was not associated with cognitive decline in healthy controls ($\beta = -.07$, $p = .49$). Self-reported depression added to the model was also not a significant predictor; age remained the only significant predictor of cognitive decline (see Table 3). The final model, which had age as its only significant predictor, accounted for 12.9% of the variance in cognitive decline.

Discussion

In this study, we found that in a premanifest HD sample, more severe apathy symptoms at baseline predicted more rapid subsequent cognitive decline over 24 months. This relationship emerged after controlling for age and depression symptoms. These findings suggest that in the context of the highly variable onset and course of cognitive decline in HD, the detection of apathy may point to an elevated risk of cognitive decline. Our findings extend previous cross-sectional studies that have documented the association between apathy and poorer cognition in HD (Baudic et al., 2006; Reedeker et al., 2011), demonstrating that prospectively, using longitudinal data, the presence of apathy symptoms is predictive of cognitive decline. Our finding in HD is also consistent with previous studies in Parkinson's disease (Dujardin et al., 2009) and Alzheimer's disease (Starkstein et al., 2006), which indicated that apathy was linked to faster cognitive decline over 1-4 years. In the current study, the premanifest group did not show evidence of significant cognitive decline over the 24 months, consistent with previous studies of cognitive decline in premanifest HD, which have demonstrated subtle declines in this population, which generally require very large samples and a longer follow up to detect significant decline (Paulsen, Smith, Long, investigators, & Coordinators of the Huntington Study, 2013). Nevertheless, the emergence of a relationship between apathy symptoms and cognitive decline in this group indicates that apathy can predict even subtle cognitive decline, that may then accelerate as the disease progresses. Given the presence of apathy is associated with frontal-striatal damage (Levy & Dubois, 2006), and the TRACK-HD cognitive battery was chosen to be most sensitive to fronto-striatal degeneration (Stout et al., 2012), it is perhaps not surprising that we found a relationship between apathy and decline on these cognitive tasks. Recent research has identified cognitive deficits in HD associated with extra-striatal brain regions (J. C. Stout, Glikmann-Johnston, & Andrews, 2016), and therefore future research should examine

whether apathy is predictive of decline in all cognitive domains in HD, or whether it is specific only to cognitive domains affected by frontal-striatal degeneration.

Our finding that the relationship between apathy and cognitive decline only emerged after controlling for depression requires some consideration in light of the well-established relationship between depression and reduced cognitive performance across healthy and many clinical populations, including HD (Knight & Baune, 2018; Pirogovsky-Turk et al., 2017; Smith et al., 2012). In contrast, we found that higher self-reported depression at baseline was associated with *less* subsequent cognitive decline in our final model. We believe this suggests that in participants with depression symptoms at baseline, some of their cognitive impairment may have been attributable to depression, and cognitive function may have improved secondary to effective treatment or spontaneous remission of depression over the study period. Another possibility is that participants with intact cognition at baseline were more self-aware of their depression symptoms, and also experienced slower cognitive decline. Supporting this hypothesis, previous research has demonstrated a relationship between cognition and awareness of neuropsychiatric symptoms (Andrews et al., 2018), and shown that cognitive decline accelerates with disease progression in HD (Paulsen et al., 2013). Further research is needed to elucidate the relationship between depression and cognitive decline in HD gene-positive people.

The contrast between our findings in premanifest HD, in which motor signs appeared to have no effect on the apathy's prediction of more rapid cognitive impairment, and our findings in early manifest HD, in which more severe motor signs, but not apathy symptoms, predicted subsequent faster cognitive decline, indicates that after motor onset, motor signs are a better predictor of cognitive decline than apathy. Previous research, and our current findings, have demonstrated that cognitive decline is more marked in early HD compared to premanifest HD (Stout et al., 2012), and that motor and cognitive progression often co-occur

(Dorsey et al., 2013; Tabrizi et al., 2013). Additionally, most cognitive tasks include a significant motor component; therefore motor impairments also often have a direct impact on cognitive performance (Hart et al., 2014; Ross et al., 2014). Hence, part of the predictive value of motor impairments on longitudinal cognitive decline might partially reflect the rate of motor progression over time. Because this project was a secondary analysis of data from TRACK-HD study, our selection of cognitive tasks was limited to those available for analysis. To minimise the influence of motor impairments on measures of cognitive decline, future studies should consider the use of cognitive tasks requiring minimal motor response, such as orally administered versions of common cognitive tasks such as the Symbol Digit Modalities Test.

Motor signs, compared to apathy, may also better predict cognitive decline due to lower levels of measurement error. As a behavioural syndrome, apathy is a challenging construct to measure. The assessment used in the current study, the PBA-s, although scored by a professional rater, is somewhat subjective and relies on a very small sample of behaviours. As such its reliability is somewhat limited. In contrast, the measurement of motor signs may be less noisy. Another consideration is that in our regression model for the early HD group, apathy was a significant predictor of cognitive decline before the inclusion of motor signs in the model. This suggests that there is substantial overlap in variance between apathy and motor signs in early HD, and therefore even with improved measurement, apathy may not be a significant independent predictor of cognitive decline in early HD. Regardless, in early HD, motor symptoms better predict the rate of cognitive decline than symptoms of apathy.

In both premanifest and early HD participants, age was also a significant predictor of cognitive decline, where younger age at baseline was associated with more rapid cognitive decline. This is likely due to the relationship among CAG expansion, age, and the timing and

severity of disease onset. Specifically, people with larger CAG expansions tend to have a younger and more severe onset of symptoms in HD, including cognitive symptoms (Penney, Vonsattel, MacDonald, Gusella, & Myers, 1997; Walker, 2007). In contrast, in healthy controls, older age was a significant predictor of faster cognitive decline, in line with the long-established effect of age on cognition (Verhaeghen & Salthouse, 1997).

This study had several strengths, including the large samples of premanifest and early HD participants, and the use of a prospective longitudinal design. With regard to limitations, although the PBA-s apathy measure is well validated, it is comprised of only a single item. Apathy is increasingly recognised as a multi-dimensional construct (Levy & Dubois, 2006), and new measures assess the cognitive, behavioural, and emotional subtypes of the syndrome (Radakovic & Abrahams, 2014). It is possible that a particular subtype of apathy (e.g., cognitive) is a better predictor of cognitive decline in HD, or that different subtypes of apathy may have differential effects on cognition. For example, behavioural apathy may be associated with reduced motivation to perform on a cognitive task, and cognitive apathy may be associated with poorer cognitive capacity in the context of intact motivation. Future studies using more comprehensive measures of apathy will likely further enhance our understanding of apathy as a predictor of cognitive decline, particularly in early HD.

In conclusion, we found that after controlling for age and depression, higher levels of apathy predicted more rapid cognitive decline in people with premanifest HD. In contrast, after clinical diagnosis of HD, which is triggered by the unequivocal presence of motor signs of HD, motor symptom severity, rather than apathy, is the best predictor of cognitive decline. Clinically, apathy in premanifest HD is a harbinger of relatively rapid cognitive decline, whereas in people with the clinical diagnosis of HD, motor signs are the harbinger of cognitive decline.

References

- Andrews, S. C., Craufurd, D., Durr, A., Leavitt, B. R., Roos, R. A., Tabrizi, S. J., Stout, J. C. & the Track HD Investigators (2018). Executive impairment is associated with unawareness of neuropsychiatric symptoms in premanifest and early Huntington's disease. *Neuropsychology*, *32*(8), 958-965. doi:10.1037/neu0000479
- Baake, V., Coppen, E. M., van Duijn, E., Dumas, E. M., van den Bogaard, S. J. A., Scahill, R. I., . . . Track HD Investigators. (2018). Apathy and atrophy of subcortical brain structures in Huntington's disease: A two-year follow-up study. *NeuroImage: Clinical*, *19*, 66-70. doi:10.1016/j.nicl.2018.03.033
- Baudic, S., Maison, P., Dolbeau, G., Boissé, M.-F., Bartolomeo, P., Dalla Barba, G., . . . Bachoud-Lévi, A.-C. (2006). Cognitive impairment related to apathy in early Huntington's disease. *Dementia and geriatric cognitive disorders*, *21*(5-6), 316-321. doi:10.1159/000091523
- Beck, A. T., Steer, R. A., & Brown, G. K. (1996). *Manual for the Beck Depression Inventory-II*. San Antonio, TX: Psychological Corporation.
- Callaghan, J., Stopford, C., Arran, N., Boisse, M. F., Coleman, A., Santos, R. D., . . . Craufurd, D. (2015). Reliability and factor structure of the Short Problem Behaviors Assessment for Huntington's disease (PBA-s) in the TRACK-HD and REGISTRY studies. *Journal of Neuropsychiatry and Clinical Neurosciences*, *27*(1), 59-64. doi:10.1176/appi.neuropsych.13070169
- Carpenter, C., & Kenward, M. (2013). *Multiple Imputation and its Application*. New York: Wiley.
- Delmaire, C., Dumas, E. M., Sharman, M. a., van den Bogaard, S. J. a., Valabregue, R., Jauffret, C., . . . Lehericy, S. (2013). The structural correlates of functional deficits in early huntington's disease. *Human Brain Mapping*, *34*(9), 2141-2153. doi:10.1002/hbm.22055
- Dorsey, E. R., Beck, C. a., Darwin, K., Nichols, P., Brocht, A. F. D., Biglan, K. M., & Shoulson, I. (2013). Natural history of Huntington disease. *JAMA neurology*, *70*(12), 1520-1530. doi:10.1001/jamaneurol.2013.4408
- Duff, K., Paulsen, J. S., Beglinger, L. J., Langbehn, D. R., Wang, C., Stout, J. C., . . . Predict HD Investigators of the HSG (2010). "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness. *J Neuropsychiatry Clin Neurosci*, *22*(2), 196-207. doi:10.1176/appi.neuropsych.22.2.196
- Dujardin, K., Sockeel, P., Delliaux, M., Destee, A., & Defebvre, L. (2009). Apathy may herald cognitive decline and dementia in Parkinson's disease. *Movement Disorders*, *24*(16), 2391-2397. doi:10.1002/mds.22843
- Garcia-Ramos, R., Villanueva, C., del Val, J., & Matias-Guiu, J. (2010). Apathy in Parkinson's disease. *Neurologia*, *25*(1), 40-50.
- Hart, E. P., Dumas, E. M., Schoonderbeek, A., Wolthuis, S. C., van Zwet, E. W., & Roos, R. A. (2014). Motor dysfunction influence on executive functioning in manifest and premanifest Huntington's disease. *Movement Disorders*, *29*(3), 320-326. doi:10.1002/mds.25806
- Hedner, M., Larsson, M., Arnold, N., Zucco, G. M., & Hummel, T. (2010). Cognitive factors in odor detection, odor discrimination, and odor identification tasks. *J Clin Exp Neuropsychol*, *32*(10), 1062-1067. doi:10.1080/13803391003683070
- Huntington Study Group. (1996). Unified Huntington's disease rating scale: reliability and consistency. *Movement Disorders*, *11*, 136-142.

- Knight, M. J., & Baune, B. T. (2018). Cognitive dysfunction in major depressive disorder. *Current Opinion in Psychiatry*, *31*(1), 26-31. doi:10.1097/YCO.0000000000000378
- Larsson, M., Finkel, D., & Pedersen, N. L. (2000). Odor identification: influences of age, gender, cognition, and personality. *J Gerontol B Psychol Sci Soc Sci*, *55*(5), P304-310. doi:10.1093/geronb/55.5.p304
- Levy, R., & Dubois, B. (2006). Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. *Cerebral Cortex*, *16*(7), 916-928. doi:10.1093/cercor/bhj043
- Martinez-Horta, S., Perez-Perez, J., Sampedro, F., Pagonabarraga, J., Horta-Barba, A., Carceller-Sindreu, M., . . . Kulisevsky, J. (2018). Structural and metabolic brain correlates of apathy in Huntington's disease. *Mov Disord*. doi:10.1002/mds.27395
- Martinez-Horta, S., Perez-Perez, J., van Duijn, E., Fernandez-Bobadilla, R., Carceller, M., Pagonabarraga, J., . . . Kulisevsky, J. (2016). Neuropsychiatric symptoms are very common in premanifest and early stage HD. *Parkinsonism & Related Disorders*, *25*, 58-64.
- McNally, G., Rickards, H., Horton, M., & Craufurd, D. (2015). Exploring the Validity of the Short Version of the Problem Behaviours Assessment (PBA-s) for Huntington's disease: A Rasch Analysis. *Journal of Huntingtons Disease*, *4*(4), 347-369. doi:10.3233/JHD-150164
- Nobis, L., & Husain, M. (2018). Apathy in Alzheimer's disease. *Curr Opin Behav Sci*, *22*, 7-13. doi:10.1016/j.cobeha.2017.12.007
- Nordin, S., Paulsen, J. S., & Murphy, C. (1995). Sensory- and memory-mediated olfactory dysfunction in Huntington's disease. *Journal of the International Neuropsychology Society*, *1*(3), 281-290. doi:10.1017/s1355617700000278
- Orth, M., Handley, O. J., Schwenke, C., Dunnett, S. B., Craufurd, D., Ho, A. K., . . . Investigators of the European Huntington's Disease, N. (2010). Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. *PLoS Currents*, *2*, RRN1184. doi:10.1371/currents.RRN1184
- Palminteri, S., Justo, D., Jauffret, C., Pavlicek, B., Dauta, A., Delmaire, C., . . . Pessiglione, M. (2012). Critical roles for anterior insula and dorsal striatum in punishment-based avoidance learning. *Neuron*, *76*(5), 998-1009. doi:10.1016/j.neuron.2012.10.017
- Papoutsis, M., Labuschagne, I., Tabrizi, S. J., & Stout, J. C. (2014). The cognitive burden in Huntington's disease: Pathology, phenotype, and mechanisms of compensation. *Movement Disorders*, *29*(5), 673-683. doi:10.1002/mds.25864
- Paulsen, J. S., & Long, J. D. (2014). Onset of Huntington's disease: can it be purely cognitive? *Movement Disorders*, *29*(11), 1342-1350. doi:10.1002/mds.25997
- Paulsen, J. S., Smith, M. M., Long, J. D., Predict HD Investigators, & Coordinators of the Huntington Study Group. (2013). Cognitive decline in prodromal Huntington Disease: implications for clinical trials. *Journal of Neurology, Neurosurgery and Psychiatry*, *84*(11), 1233-1239. doi:10.1136/jnnp-2013-305114
- Penney, J. B., Jr., Vonsattel, J. P., MacDonald, M. E., Gusella, J. F., & Myers, R. H. (1997). CAG repeat number governs the development rate of pathology in Huntington's disease. *Annals of Neurology*, *41*(5), 689-692. doi:10.1002/ana.410410521
- Pirogovsky-Turk, E., Moore, R. C., Filoteo, J. V., Litvan, I., Song, D. D., Lessig, S. L., & Schiehser, D. M. (2017). Neuropsychiatric Predictors of Cognitive Decline in Parkinson Disease: A Longitudinal Study. *American Journal of Geriatric Psychiatry*, *25*(3), 279-289. doi:10.1016/j.jagp.2016.10.004
- Radakovic, R., & Abrahams, S. (2014). Developing a new apathy measurement scale: Dimensional Apathy Scale. *Psychiatry Research*, *219*(3), 658-663. doi:10.1016/j.psychres.2014.06.010

- Reedeker, N., Bouwens, J. A., van Duijn, E., Giltay, E. J., Roos, R. A. C., & van der Mast, R. C. (2011). Incidence, Course, and Predictors of Apathy in Huntington's Disease: A Two-Year Prospective Study. *The Journal of Neuropsychiatry and Clinical Neurosciences*, 23(4), 434-441.
- Richard, E., Schmand, B., Eikelenboom, P., Yang, S. C., Ligthart, S. A., Moll van Charante, E. P., . . . Alzheimer's Disease Neuroimaging Investigators. (2012). Symptoms of apathy are associated with progression from mild cognitive impairment to Alzheimer's disease in non-depressed subjects. *Dementia and Geriatric Cognitive Disorders*, 33(2-3), 204-209. doi:10.1159/000338239
- Robert, P. H., Berr, C., Volteau, M., Bertogliati-Fileau, C., Benoit, M., Guerin, O., . . . Pre, A. L. S. G. (2008). Importance of lack of interest in patients with mild cognitive impairment. *American Journal of Geriatric Psychiatry*, 16(9), 770-776. doi:10.1097/JGP.0b013e31817e73db
- Ross, C. A., Pantelyat, A., Kogan, J., & Brandt, J. (2014). Determinants of functional disability in Huntington's disease: role of cognitive and motor dysfunction. *Movement Disorders*, 29(11), 1351-1358. doi:10.1002/mds.26012
- Rubin, D. B. (1987). *Multiple Imputation for Nonresponses in Surveys*. New York: Wiley.
- SAS Institute Inc. (2015). SAS/STAT 14.0. Cary, NC, USA.
- Schab, F. R. (1991). Odor memory: taking stock. *Psychological Bulletin*, 109(2), 242-251. doi:10.1037/0033-2909.109.2.242
- Shoulson, I., & Fahn, S. (1979). Huntington's disease: clinical care and evaluation. *Neurology*, 29(1), 1-3.
- Smith, M. M., Mills, J. A., Epping, E. A., Westervelt, H. J., Paulsen, J. S., & Group, P.-H. I. o. t. H. S. (2012). Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease. *Neuropsychology*, 26(5), 664-669. doi:10.1037/a0029218
- Sousa, M., Moreira, F., Jesus-Ribeiro, J., Marques, I., Cunha, F., Canario, N., . . . Janeiro, C. (2018). Apathy Profile in Parkinson's and Huntington's Disease: A Comparative Cross-Sectional Study. *European Neurology*, 79(1-2), 13-20. doi:10.1159/000481981
- Starkstein, S. E., Jorge, R., Mizrahi, R., & Robinson, R. G. (2006). A prospective longitudinal study of apathy in Alzheimer's disease. *Journal of Neurology Neurosurgery and Psychiatry*, 77(1), 8-11. doi:10.1136/jnnp.2005.069575
- Stout, J. C., Glikmann-Johnston, Y., & Andrews, S. C. (2016). Cognitive assessment strategies in Huntington's disease research. *Journal of Neuroscience Methods*, 265, 19-24. doi:10.1016/j.jneumeth.2015.12.007
- Stout, J. C., Jones, R., Labuschagne, I., O'Regan, A. M., Say, M. J., Dumas, E. M., . . . Frost, C. (2012). Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. *Journal of Neurology, Neurosurgery, and Psychiatry*, 83(7), 687-694. doi:10.1136/jnnp-2011-301940
- Stout, J. C., Paulsen, J. S., Queller, S., Solomon, A. C., Whitlock, K. B., Campbell, J. C., . . . Aylward, E. H. (2011). Neurocognitive signs in prodromal Huntington disease. *Neuropsychology*, 25(1), 1-14. doi:10.1037/a0020937
- Tabrizi, S. J., Langbehn, D. R., Leavitt, B. R., Roos, R. A., Durr, A., Craufurd, D., . . . Stout, J. C. (2009). Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. *The Lancet. Neurology*, 8(9), 791-801. doi:10.1016/S1474-4422(09)70170-X
- Tabrizi, S. J., Scahill, R. I., Owen, G., Durr, A., Leavitt, B. R., Roos, R. A., . . . Track HD Investigators (2013). Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis

of 36-month observational data. *The Lancet Neurology*, *12*(7), 637-649.

doi:10.1016/S1474-4422(13)70088-7

Verhaeghen, P., & Salthouse, T. A. (1997). Meta-analyses of age-cognition relations in adulthood: estimates of linear and nonlinear age effects and structural models.

Psychological Bulletin, *122*(3), 231-249.

Walker, F. O. (2007). Huntington's disease. *The Lancet*, *369*, 218-228. doi:10.1016/S0140-6736(07)60111-1

Figure Legend


Mean (SD) of change in composite score over 24 months in each group

Figure 1. Mean (Standard Deviation) of change in cognitive composite score over 24 months for each group, based on the multiple imputation data.

Financial Support

TRACK-HD was supported by CHDI/High Q Foundation Inc, a not for profit organisation dedicated to finding treatments for Huntington's disease. CHDI provided funding to University College London (UCL), and UCL provided funding to Monash University. STJ was global Principal Investigator for the TRACK-HD study, and JCS was Principal Investigator for the Monash University component of TRACK-HD.

Conflicts of interest

None

Ethical Standards

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.